View Older Stories

Nov 24, 2025 07:02AM Arvinas to present vepdegestrant data at breast cancer symposium

Nov 10, 2025 06:33AM Arvinas Inc. (ARVN) PT Raised to $15 at Stephens

Nov 5, 2025 07:18AM Arvinas, Inc. (ARVN) Tops Q3 EPS by 23c

Nov 3, 2025 04:00PM Arvinas to present ARV-393 data at ASH meeting in december

Oct 30, 2025 06:05AM Arvinas Inc. (ARVN) PT Raised to $14 at BTIG

Oct 24, 2025 04:00PM Arvinas presents preclinical data for cancer drug ARV-806

Oct 22, 2025 04:00PM Arvinas to present ARV-806 cancer drug data at October conference

Oct 15, 2025 02:42AM Goldman Sachs Downgrades Arvinas Inc. (ARVN) to Sell

Oct 7, 2025 08:27AM Arvinas Inc. (ARVN) PT Raised to $16 at Piper Sandler

Oct 6, 2025 09:08AM Arvinas Inc. (ARVN) PT Raised to $12 at BofA Securities

Sep 24, 2025 02:35AM BofA Securities Downgrades Arvinas Inc. (ARVN) to Neutral

Sep 19, 2025 06:50AM H.C. Wainwright Reiterates Buy Rating on Arvinas Inc. (ARVN)

Sep 19, 2025 04:47AM Arvinas Inc. (ARVN) PT Lowered to $15 at Barclays

Sep 18, 2025 06:52AM Cantor Fitzgerald Reiterates Overweight Rating on Arvinas Inc. (ARVN)

Sep 18, 2025 06:49AM Arvinas Inc. (ARVN) PT Lowered to $9 at Wedbush

Sep 18, 2025 06:41AM Arvinas Inc. (ARVN) PT Lowered to $14 at Stephens

Sep 17, 2025 04:31PM Arvinas and Pfizer to out-license vepdegestrant commercialization rights

Sep 17, 2025 04:37AM Barclays Starts Arvinas Inc. (ARVN) at Overweight

Aug 8, 2025 04:05PM FDA accepts Arvinas drug application for advanced breast cancer treatment

Aug 7, 2025 06:53AM Arvinas Inc. (ARVN) PT Lowered to $15 at Guggenheim

Aug 6, 2025 07:50AM Arvinas, Inc. (ARVN) Tops Q2 EPS by 10c

Jul 9, 2025 07:00AM Arvinas CEO John Houston announces retirement plans

Jun 6, 2025 08:38AM Arvinas (ARVN) stock rises on FDA submission with Pfizer (PFE)

Jun 6, 2025 07:01AM Arvinas Inc. (ARVN) Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

Jun 3, 2025 07:05AM H.C. Wainwright Reiterates Buy Rating on Arvinas Inc. (ARVN)

Jun 2, 2025 01:10AM Leerink Partners Downgrades Arvinas Inc. (ARVN) to Market Perform

May 30, 2025 05:01AM Citizens JMP: Standard of Care Modifying Regimens at ASCO 2025

May 7, 2025 10:10AM Arvinas, Inc. (ARVN) Investors May Be Able to Recover Losses By Reaching Out To Block & Leviton Regarding Securities Fraud Investigation

May 5, 2025 06:58AM Arvinas Inc. (ARVN) PT Lowered to $24 at H.C. Wainwright

May 5, 2025 04:56AM Arvinas Inc. (ARVN) PT Lowered to $9.50 at Citi

May 5, 2025 01:04AM Truist Securities Downgrades Arvinas Inc. (ARVN) to Hold

May 2, 2025 05:35AM Arvinas Inc. (ARVN) PT Lowered to $16 at BTIG

May 2, 2025 05:30AM TD Cowen Downgrades Arvinas Inc. (ARVN) to Hold

May 1, 2025 04:30PM Jefferies Downgrades Arvinas Inc. (ARVN) to Hold

May 1, 2025 04:05PM Arvinas Inc. (ARVN) PT Lowered to $8 at Goldman Sachs

May 1, 2025 07:07AM Arvinas, Inc. (ARVN) Tops Q1 EPS by 214c

Apr 23, 2025 10:45AM Arvinas (ARVN) Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology

Apr 9, 2025 09:34AM Arvinas Inc. (ARVN) PT Lowered to $21 at Truist Securities

Apr 8, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Arvinas Inc. (ARVN)

Apr 4, 2025 07:01AM Arvinas Inc. (ARVN) Presents First-in-Human Data for Investigational Oral PROTAC ARV-102

Mar 17, 2025 07:06AM Cantor Fitzgerald says 15% of biotech companies down 40% or more

Mar 12, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Arvinas Inc. (ARVN)

Mar 12, 2025 06:30AM Arvinas Inc. (ARVN) PT Lowered to $20 at BMO Capital

Mar 12, 2025 05:28AM BTIG Reiterates Buy Rating on Arvinas Inc. (ARVN)

Mar 11, 2025 03:52PM Arvinas Inc. (ARVN) PT Lowered to $10 at Citi

Mar 11, 2025 10:13AM Oppenheimer Downgrades Arvinas Inc. (ARVN) to Perform

Mar 11, 2025 06:46AM Arvinas Inc. (ARVN) and Pfizer (PFE) Announce Positive Topline Results from Phase 3 VERITAC-2 Trial

Feb 12, 2025 10:30AM UBS Reiterates Buy Rating on Arvinas Inc. (ARVN)

Feb 12, 2025 07:43AM Arvinas Inc. (ARVN) PT Lowered to $51 at Stifel

Feb 12, 2025 06:44AM Arvinas Inc. (ARVN) PT Lowered to $81 at H.C. Wainwright

View Older Stories